We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 3,706

District Court Finds Hospital’s Joint Venture Not “Per Se” Unlawful
  • Mintz Levin
  • USA
  • August 16 2017

On the eve of trial, and after years of litigation (including an appeal to the Sixth Circuit), all claims by Dayton, Ohio hospital The Medical Center


Dayton Hospital Antitrust Case Comes to an End: Joint Venture Activities Not “Per Se” Unlawful
  • Mintz Levin
  • USA
  • August 16 2017

On the eve of trial, and after years of litigation (including an appeal to the Sixth Circuit), all claims by Dayton, Ohio hospital The Medical Center


FTC Competition Director Highlights Enforcement Priorities in the Pharmaceutical Industry
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 3 2017

Last week Markus Meier, the Acting Director of the Bureau of Competition at the Federal Trade Commission, gave testimony to the House Judiciary


Implications of Certiorari Denial in Belmora v. Bayer Consumer Care
  • Fenwick & West LLP
  • USA
  • July 27 2017

Belmora LLC v. Bayer Consumer Care AG (Belmora I), a significant and long-running trademark and unfair competition case that questioned whether the


Health Care Mergers: Four Key Pieces of Evidence Used to Predict The Future
  • Winston & Strawn LLP
  • USA
  • July 26 2017

The federal government challenges proposed mergers through Section 7 of the Clayton Act, which prohibits any acquisition within the realm of commerce


The FTC Continues to Challenge Healthcare Mergers
  • Manatt Phelps & Phillips LLP
  • USA
  • July 24 2017

Confirming that hospital merger enforcement continues to be a priority under the new administration, the Federal Trade Commission (FTC) and the North


Opportunity - FDA encouraging manufacture and distribution of new generic drugs
  • Innofy
  • USA
  • July 21 2017

The U.S. Food and Drug Administration (FDA) are desperately seeking to increase competition for prescription drugs. The reasons for this are of no


The Supreme Court’s Decision in Amgen v. Sandoz: Clear Guidance and Open Questions for Biosimilars
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • July 21 2017

As we previously reported here, earlier this year the Supreme Court agreed to hear its first case arising under the Biosimilars Price Competition and


FDA Holds Public Meeting on Innovation in Drug Development and Accelerating Access to Generic Medicines
  • Arent Fox LLP
  • USA
  • July 20 2017

On July 18, 2017, FDA held a public meeting to address efforts to ensure a balance between innovation in drug development and Accelerating the access


FDA Increases Priority Review Opportunities for Drug Products with Limited Competition
  • Duane Morris LLP
  • USA
  • July 18 2017

The FDA hopes to increase market competition for prescription drugs and facilitate entry of lower-cost alternatives. Following the Drug Competition